Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Deric Park

Diagnostic Neuroimaging Chicago, IL Medical Doctor

NPI 1730391509 CMS profile 498385

5841 S Maryland Ave # Mc2030, Chicago, IL 60637

Open in the dashboard

General payments

$6,864

26 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$80,293 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Deric Park of Chicago, IL is reported in the CMS Open Payments database as having received $6,864 across 26 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $80,293 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $281 8
2024 General $398 8
2023 General $6,036 8
2022 General $14 1
2019 General $135 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deric Park
  • Illinois median
  • Middle half of Illinois
  • National median

In program year 2025, general payments to Deric Park were reported at $281. Among 38,505 Illinois profiles paid that year, the median was $163 and the middle half received between $50 and $568.

Show as a table
Year Deric Park Illinois median Middle half National median
2019 $135 $151 $49–$575 $163
2020 $0 $105 $32–$363 $114
2021 $0 $124 $36–$426 $132
2022 $14 $138 $41–$499 $149
2023 $6,036 $148 $45–$517 $160
2024 $398 $154 $47–$535 $164
2025 $281 $163 $50–$568 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novocure Inc. $6,558 16 payments
  2. SK Life Science, Inc. $147 1 payment
  3. Servier Pharmaceuticals LLC $35 2 payments
  4. Merck Sharp & Dohme Corporation $34 2 payments
  5. Janssen Biotech, Inc. $32 2 payments
  6. Caris MPI, Inc. $27 1 payment
  7. Cumberland Pharmaceuticals, Inc. $17 1 payment
  8. Biohaven Pharmaceutical Holding Company Ltd. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $5,400 1 payment
  2. Food and Beverage $1,325 23 payments
  3. Travel and Lodging $121 1 payment
  4. Education $18 1 payment
Products named General payments · program years 2019–2025
  1. Optune Oncology $5,821 5 payments
  2. Optune Oncology $218 5 payments
  3. Optune Gio $170 2 payments
  4. Oncology $135 1 payment
  5. WELIREG $34 2 payments
  6. RYBREVANT $32 2 payments
  7. MI CANCER SEEK $27 1 payment
  8. Voranigo $17 1 payment
  9. SANCUSO $17 1 payment
  10. NURTEC ODT $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

196

Median for Neurology: 833

Drug cost

$3,768

Median for Neurology: $202,670

Branded share of claims

8.2%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Levetiracetam Generic 63 $1,046
Ondansetron Hcl Generic 20 $980
Lacosamide Generic 23 $712
Dexamethasone Generic 41 $590
Famotidine Generic 19 $177
Duloxetine Hcl Generic 14 $175
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 16 $88

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$57,214

Medicare's payments for the services billed

Medicare patients

161

Average age 72

Services billed

655

91 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 55%
Arthritis 50%
Ischemic heart disease 41%
Diabetes 33%
Depression 32%
COPD 24%
Chronic kidney disease 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WELIREG
  • Merck Sharp & Dohme Corporation $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

26 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Neuroimaging in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record